百济神州：前三季度归母净利润11.39亿元

Core Insights - The company reported a total revenue of 27.595 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 44.2% [1] - The net profit attributable to the parent company's shareholders was 1.139 billion yuan, driven by the sales growth of self-developed products such as Baiyueze® (Zebutinib capsules) and Amgen authorized products, as well as Baizean® (Trelagliptin injection) [1] - The company anticipates submitting a marketing application for marginal zone lymphoma in Japan in the first half of 2026, with expectations of obtaining orphan drug designation [1]